1,853 material Form 8-K filings that 1,500 companies we cover made with the SEC in September 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
HIVE Digital Technologies said on September 10, 2026 that its estimated average daily revenue from hashrate and GPU services exceeded approximately $1 million per day, based on preliminary, unaudited information. It also appointed Mark Volk as Senior Vice President, Revenue of its subsidiary BUZZ High Performance Computing, and said it plans to wind down Bitcoin mining at its Swedish facilities to repurpose that infrastructure toward HPC and AI uses.
Estimated average daily revenue exceeded approximately $1 million since August 21, 2026; the company says this is not a forecast and has not been through its normal quarter-end closing procedures.
GPU cloud operations generated approximately $100,000 in average daily revenue, and the company reports closing more than $600 million in total contract value year to date.
Swedish Bitcoin mining represented less than 5% of global daily revenue during August; the company intends to wind it down.
Mark Volk, a former HPE and IBM executive who has consulted for the company for about nine months, reports to Craig Tavares, President and COO of BUZZ HPC.
Expand Energy Corporation priced a $500 million underwritten offering of 5.650% senior notes due 2031 at 99.889% of face value. The company said it expects to close the offering on September 17, 2026, and intends to use the net proceeds for general corporate purposes.
Offering size: $500,000,000 aggregate principal amount of 5.650% senior notes due 2031
Price to the public: 99.889% of face value
Expected closing date: September 17, 2026
Use of net proceeds: general corporate purposes; underwriters were Citigroup Global Markets Inc. and J.P. Morgan Securities LLC
AEye, Inc. entered into an at-the-market sales agreement with A.G.P./Alliance Global Partners allowing it to sell up to $50,000,000 of common stock from time to time, and ended its prior sales agreement with the same agent. The company is under no obligation to sell any shares and may suspend sales at any time, but any shares sold would add to the existing share count and dilute current shareholders.
Up to $50,000,000 of common stock may be sold through A.G.P. under a shelf registration on Form S-3.
Commissions of up to 3.0% of gross proceeds are payable to A.G.P., plus up to 1.0% in advisory fees to Craig-Hallum Capital Group LLC.
The agreement replaces the prior sales agreement dated September 12, 2024, with no early termination penalties, and runs up to 36 months.
Proceeds are intended for working capital and general corporate purposes, including aerospace, defense and infrastructure markets.
Liberty Latin America disclosed term sheets exchanged with holders of debt at its Liberty Puerto Rico (LPR) subsidiaries during restructuring talks, and said those negotiations are not continuing. The company states that no agreement has been reached and that none is assured, so the outcome for LLA shareholders remains unresolved. The proposals show that LLA's equity stake and the debt structure could change materially.
Term sheets are dated August 26, August 30, September 9 and September 11, 2026, and cover a restructuring of LPR debt, including a proposed $410 million of new money first-out notes at a 6.50% rate.
An LLA proposal of August 26, 2026 includes $1,250 million of second-out takeback debt at 8.00% and 25% of pro forma equity for LLA, plus warrants.
A SteerCo counterproposal dated August 30, 2026 shows LLA common equity as fully extinguished for no consideration.
LLA disputes any claim by LPR or its bondholders tied to about $410 million? No: LLA disputes any claim tied to distributions made from LPR bond proceeds, citing disclosures and records provided on August 28, September 1 and September 2, 20
On September 15, 2026, iPower completed an additional optional closing under its convertible note facility with an institutional investor, issuing $3,000,000 of Series A senior secured convertible notes for $2,820,000 before fees and expenses. The notes carry a fixed conversion price of $3.156, and the filing says $9,084,580 of Series A notes have already been converted to date, which adds potential dilution for shareholders.
Issued $3,000,000 principal of Series A notes on September 15, 2026, at $940 per $1,000 of principal
Received about $2,820,000 gross proceeds before fees; a 6% cash fee is payable to placement agent Digital Offering
Fixed conversion price of $3.156, set at 120% of the Nasdaq closing price on September 15, 2026
Total Series A notes sold to date: $15,184,024; $15,000,000 remains available; $9,084,580 converted to date
On September 15, 2026, Uber completed a registered public offering of five series of senior unsecured notes totaling €4.5 billion, issued under its Form S-3 registration statement. The company intends to use the net proceeds for general corporate purposes, and the filing does not state the net proceeds amount.
Notes priced at 3.750% due 2029 (€750 million), 4.125% due 2032 (€1.0 billion), 4.375% due 2034 (€1.0 billion), 4.750% due 2038 (€1.0 billion) and 5.250% due 2046 (€750 million)
Goldman Sachs & Co. LLC, Morgan Stanley & Co. International plc, Deutsche Bank AG, London Branch, Merrill Lynch International and BNP PARIBAS are named as representatives of the underwriters
Notes were issued under a base indenture dated September 9, 2024 and a Third Supplemental Indenture dated September 15, 2026, with U.S. Bank Trust Company, National Association as trustee
Proceeds are intended for general corporate purposes
authID entered a Backstop Commitment Agreement on September 9, 2026 with holders of its senior secured debentures, and $300,000 was funded on September 11, 2026. The agreement also fixes the debenture conversion price at $0.38, reduces existing warrant exercise prices from $1.50 to $0.57, and issues 750,000 commitment fee warrants, which could dilute shareholders. Share issuance under these securities is capped at 19.99% of prior outstanding shares absent stockholder approval.
Backstop commitment of up to $300,000 or $500,000, depending on whether a strategic investor funding transaction occurs; $300,000 was funded on September 11, 2026.
Existing warrant exercise price reduced from $1.50 to $0.57 per share; debenture conversion price fixed at $0.38.
750,000 commitment fee warrants issued at a $0.57 exercise price with a five-year term.
Nasdaq rules cap share issuance at 19.99% of shares outstanding before the April 29, 2026 purchase agreement without stockholder approval.
USA Rare Earth filed a supplement to its risk factors, attaching an updated set as Exhibit 99.1 that adds disclosures tied to the Serra Verde (SVRE) merger agreement dated April 19, 2026. The filing reports a 2025 net loss of $298.5 million and says that delays at Less Common Metals have affected production at the Stillwater Facility, which matters to shareholders because it adds detail on the company's losses, feedstock supply and lack of signed customer contracts.
Net loss of $298.5 million for the year ended December 31, 2025; accumulated deficit of $387.4 million as of that date.
Merger Agreement dated April 19, 2026 among USAR, Merger Sub, SVRE and Serra Verde Rare Earths Ltd. is referenced.
Less Common Metals is experiencing delays in supplying metal feedstock to the Stillwater Facility, which has affected production there.
The company states it has no revenue or definitive offtake or sales agreements with customers in its magnet business.
JBS S.A., a wholly-owned Brazilian subsidiary of JBS N.V., signed an association agreement on September 15, 2026 with Viva Holding to combine the leather production and processing assets of JBS S.A. and Viva into a company named JBS Viva. Completion depends on customary conditions precedent and is not guaranteed in timing or at all, so shareholders should view the deal as pending rather than closed.
JBS Viva will be owned 50% by JBS S.A. and 50% by Viva Holding after closing, with parity governance and a six-member board.
JBS S.A. will contribute its leather division entity JBS Couros in exchange for new JBS Viva shares.
Excluded from the transaction are collagen and gelatin assets, the Cactus, Texas leather operations, and JBS S.A. leather assets in Germany, Uruguay and Mexico.
The filing does not disclose any purchase price, financial terms or expected closing date.
Forward Industries said it sent a letter to the SkyAI board proposing to acquire all of SkyAI's outstanding common stock. Each SkyAI share would convert into 0.306 Forward shares at a fixed ratio, which implies $2.13 per SkyAI share based on Forward's $6.95 close on September 14, 2026, a 50% premium to SkyAI's $1.42 close that day. The proposal is non-binding and depends on due diligence, a definitive agreement, regulatory approvals and SkyAI stockholder approval, and Forward has asked for a board response by September 25, 2026.
Fixed exchange ratio of 0.306 Forward shares per SkyAI share, implying $2.13 per SkyAI share at Forward's $6.95 close on September 14, 2026.
Implied price is a 50% premium to SkyAI's $1.42 closing price on September 14, 2026.
SkyAI stockholders could elect cash, Forward common stock, or a combination of the two.
Forward requested a SkyAI board response by 5:00 p.m. Eastern time on September 25, 2026; the proposal is non-binding.
Beta Bionics said the FDA cleared its Mint patch pump and that it submitted a 510(k) application for its 3D Intelligence algorithm. It also lowered its 2026 full-year revenue estimate from $131 million to $136 million to $121 million to $126 million, citing a possible deferral of up to $10 million in the fourth quarter as new iLet users may wait for Mint. The filing also discloses a securities class action filed September 4, 2026, which the company says it intends to defend vigorously.
2026 total revenue estimate cut to $121 million to $126 million, from $131 million to $136 million; the company cites a deferral of up to $10 million in Q4 2026
Mint full U.S. commercial launch expected in Q1 2027, ahead of the previous target; manufacturing capacity of at least 1.5 million disposable units in 2027
Expected initial pharmacy coverage of about 40% of insured U.S. lives, rising to at least 50% within the first year of full commercialization
Holtzman v. Beta Bionics, Inc. securities class action filed September 4, 2026 in the Central District of California; potential loss not currently probable or estimable
CDW LLC and CDW Finance Corporation agreed on September 14, 2026 to issue and sell $1.5 billion of senior notes in a registered public offering, with CDW Corporation as guarantor. The offering is expected to close on September 21, 2026, subject to customary closing conditions. The filing is a debt financing; it does not report new earnings, guidance, or changes in operations.
$600 million of 5.700% Senior Notes due 2029
$500 million of 6.100% Senior Notes due 2032 and $400 million of 6.350% Senior Notes due 2033
Underwriters include BofA Securities, J.P. Morgan, Mizuho and Wells Fargo Securities; closing expected September 21, 2026
Evolution Petroleum reported fiscal fourth-quarter 2026 revenue of $24.2 million, up 15% from a year earlier, and net income of $4.6 million, compared with $3.4 million a year earlier. Adjusted EBITDA fell to $6.5 million from $8.6 million, and excluding selected items the company posted an adjusted net loss of $0.6 million versus adjusted net income of $1.1 million a year earlier. The company also declared a $0.12 per share dividend payable September 30, 2026.
Q4 revenue was $24.2 million, up 15% year over year, driven by a 20% increase in average realized prices, partly offset by a 4% drop in production to 6,901 BOEPD.
Q4 net income was $4.6 million, or $0.13 per diluted share, compared with a net loss of $8.9 million in fiscal Q3 2026.
Fiscal 2026 net loss was $2.4 million versus net income of $1.5 million in fiscal 2025; full-year revenue was $86.3 million.
Dividend of $0.12 per share is payable September 30, 2026, to holders of record on September 21, 2026.
ONEOK, L.L.C. (OpCo) said holders validly tendered enough notes by the September 14, 2026 early deadline to reach its $2 billion maximum, and it expects to accept and pay for $2 billion of principal on September 17, 2026. Notes in series 15 through 20 will not be purchased, and OpCo does not expect to accept tenders made after the early deadline. The filing also amends a $1 billion equity distribution agreement to reflect the company's post-reorganization structure, which is an administrative update to the existing share sale program.
OpCo expects to accept $2 billion aggregate principal amount of notes, with settlement expected September 17, 2026
Early Tender Consideration per $1,000 principal ranged from $707.44 (3.950% notes due 2050) to $955.41 (3.400% notes due 2029); late tenders receive $50 less
Amendment No. 1 dated September 15, 2026 updates the $1 billion equity distribution agreement with BofA Securities and ONEOK assumed Legacy ONEOK's obligations
First Financial Bancorp appointed James M. Anderson as president of the Company and First Financial Bank effective September 14, 2026, as part of its succession planning. Anderson keeps his role as chief financial officer and gives up the chief operating officer post, which Malcolm A. Myers took on the same day. The filing also sets new pay terms for several executives and updates severance terms for CEO Archie M. Brown.
James M. Anderson appointed president effective September 14, 2026, while retaining the CFO role; he no longer serves as COO
Amanda N. Neeley named chief banking officer and Malcolm A. Myers named chief operating officer, both effective September 14, 2026
Anderson's base salary rises 4.9% to $640,000; Brown receives a one-time restricted stock grant valued at $3 million
Brown's amended employment agreement provides three years of base salary in cash severance if terminated without cause or for good reason
Flag Ship Acquisition Corp, a blank-check company, signed a merger agreement on September 15, 2026 with Bluechip & Co. Holdings, a Cayman Islands holding company with insurance-related, advisory, advertising and data-center businesses. Bluechip shareholders would receive an aggregate of 40,000,000 Purchaser ordinary shares, reflecting a Company Net Value of $400,000,000, and the deal remains subject to shareholder approvals, a registration statement and Nasdaq listing approval.
Bluechip shareholders would receive an aggregate of 40,000,000 Purchaser ordinary shares, based on a Company Net Value of $400,000,000 at $10.00 per share.
Closing is subject to Flag Ship and Bluechip shareholder approvals, effectiveness of a Form F-4 registration statement, and Nasdaq Capital Market listing approval.
Expense loans from Bluechip to Flag Ship are non-interest-bearing and not due before June 20, 2027.
Post-closing board is expected to have five directors, including Bluechip CEO Ming Zhang.
RTX said Shane Eddy will step down as president of Pratt & Whitney effective January 1, 2027, and retire from the company at the end of the first quarter of 2027. Jill Albertelli, currently president of Pratt & Whitney's Military Engines business, has been named to succeed him. The change is a senior leadership transition for a major RTX business unit, with no financial results disclosed in the filing.
Shane Eddy steps down as Pratt & Whitney president effective January 1, 2027, and retires at the end of Q1 2027
Jill Albertelli, currently president of Pratt & Whitney Military Engines, succeeds him effective January 1, 2027
Eddy will remain with the company through March 2027 as a special advisor to support the transition
Albertelli reports to RTX chairman and CEO Chris Calio
Capital Southwest Corporation sold $350.0 million of 6.750% Notes due 2031 under an underwriting agreement dated September 10, 2026, and the offering closed September 15, 2026. The company expects net proceeds of about $342.1 million and plans to use them to repay part of its senior secured revolving credit facility, adding longer-term unsecured debt to its capital structure.
Principal amount: $350.0 million of 6.750% Notes due September 15, 2031
Net proceeds to the company: approximately $342.1 million at 98.985% of par, after a $3.5 million underwriting discount and about $0.9 million in estimated offering expenses
Proceeds intended to repay a portion of borrowings under the Corporate Credit Facility
Interest payable semi-annually on March 15 and September 15, beginning March 15, 2027
Dell subsidiaries Dell International L.L.C. and EMC Corporation completed a public offering of $5.0 billion in senior notes in four tranches, maturing from 2029 to 2037. The notes are unsecured and guaranteed by Dell Technologies Inc. and two of its wholly-owned subsidiaries, so the parent company's guarantee adds new direct obligations for shareholders to track.
Four tranches: $1.25 billion at 5.100% due 2029, $1.25 billion at 5.400% due 2031, $1.5 billion at 5.600% due 2033, and $1.0 billion at 5.900% due 2037.
Interest accrues from September 15, 2026, paid semi-annually, with the first payments due March 15, 2027 (2029, 2031, 2033 notes) and April 1, 2027 (2037 notes).
Notes are sold under a shelf registration statement on Form S-3ASR and governed by a base indenture dated January 24, 2023, with The Bank of New York Mellon Trust Company, N.A. as trustee.
Holders may require repurchase at 101% of principal upon a change of control triggering event.
On September 11, 2026, a subsidiary of Blue Owl Technology Finance Corp. (OTF) executed an amendment to its loan financing agreement, raising the maximum principal amount from $150 million to $250 million and modifying the borrowing base test conditions. The filing describes a financing arrangement at a subsidiary level, and the company has not stated how the change affects its overall results or shareholders.
Maximum principal amount increased from $150 million to $250 million.
Amendment executed September 11, 2026, by subsidiary Athena Funding III LLC as borrower.
Deutsche Bank AG, New York Branch, serves as facility agent; State Street Bank and Trust Company is collateral agent and custodian.
Amendment also modifies the conditions of the borrowing base test.
Bar Harbor Bankshares said Executive Vice President and Chief Lending Officer John M. Mercier has notified the board of his intent to retire effective December 31, 2026. He will remain in his role until that date, so the change is planned and does not take effect immediately.
John M. Mercier, EVP and Chief Lending Officer of Bar Harbor Bankshares and Bar Harbor Bank & Trust, gave notice of retirement on September 15, 2026.
Retirement is effective December 31, 2026.
Mercier will continue as EVP and Chief Lending Officer until the retirement date.
Ventas, Inc. approved the appointment of Laurida Sayed as Senior Vice President, Chief Accounting Officer and Controller, effective on or around October 5, 2026. CFO Robert F. Probst, who has been serving as interim Chief Accounting Officer, will stop in that role and remain Chief Financial Officer. The filing describes a routine finance leadership change with compensation terms disclosed but no change to reported results.
Laurida Sayed, age 44, was approved on September 10, 2026 as Chief Accounting Officer and Controller, effective on or around October 5, 2026.
Sayed's offer letter provides a $500,000 annual base salary and a target annual bonus of 60% of base salary.
Sayed receives a $150,000 one-time cash sign-on bonus and restricted stock units with a $350,000 grant date fair value that vest ratably over three years.
Robert F. Probst will remain Chief Financial Officer and stops serving as interim Chief Accounting Officer on the effective date.
Uranium Royalty Corp. reported results for the quarter ended July 31, 2026, with net income of $16.3 million, up from $1.0 million a year earlier, and diluted earnings per share of $0.10 versus $0.01. The company sold 593,255 pounds of U3O8 for $51.0 million revenue, and it used part of those proceeds to help finance its Sweetwater acquisition, completed in July 2026. Earnings rose sharply, but the filing gives no prior-year revenue or cost comparison and no guidance.
Revenue of $51.0 million from sales of 593,255 pounds of U3O8 at an average realized price of about $86.00 per pound
Net income of $16.3 million versus $1.0 million for the same period in 2025
Diluted EPS of $0.10 versus $0.01 a year earlier
Sweetwater acquisition completed in July 2026, partly funded by uranium sales
Ares Capital Corporation closed a $750 million offering of 6.250% unsecured notes due September 15, 2033, on September 15, 2026. The company said it expects to use the net proceeds to repay certain outstanding indebtedness under its credit facilities, and it may reborrow under those facilities for general corporate purposes, including investments in portfolio companies.
Notes: $750,000,000 principal, 6.250% annual interest paid semiannually, first payment March 15, 2027
Maturity September 15, 2033; redeemable in whole or part at the company's option
Concurrent interest rate swap with JPMorgan Chase Bank, N.A. converts the fixed rate to three-month SOFR plus 1.85250%, maturing September 15, 2033
Harte Hanks disclosed that the go-shop period under its August 14, 2026 merger agreement with Star Equity Holdings has expired, and that it received Acquisition Proposals during that period and gave Star an Exempted Party designation notice on September 11, 2026. The Board has not determined that any proposal is a Superior Proposal and has reaffirmed its recommendation of the Star merger, so the Star deal remains in effect.
Go-shop period expired; the company solicited interest from 93 third parties and received Acquisition Proposals before expiration.
Exempted Party designation notice delivered to Star on September 11, 2026; Board has not determined any proposal is a Superior Proposal.
Star deal terms: $5.00 in cash or 0.50 shares of Star 10% Series A Cumulative Perpetual Preferred Stock per eligible share, with cash capped at $19.2 million.
Termination fee of $1,152,000 payable to Star if the company terminates to enter a Superior Proposal after the go-shop period.
Walker & Dunlop and its subsidiary Walker & Dunlop, LLC signed Amendment No. 9 to a Master Repurchase Agreement with JPMorgan Chase Bank, N.A., extending the termination date to September 9, 2027. The company remains guarantor of the subsidiary's obligations, and a new side letter sets out fees, commitments and pricing for the facility.
Amendment No. 9 dated September 9, 2026 extends the Termination Date to September 9, 2027.
Walker & Dunlop, Inc. continues to guarantee the Seller's obligations under the agreement.
A Third Amended and Restated Side Letter dated September 9, 2026 replaces the Second Amended and Restated Side Letter dated September 11, 2025.
The filing does not state the facility size or pricing figures, which are in the redacted exhibits.
At the September 10, 2026 annual meeting, stockholders approved the 2026 Omnibus Equity Incentive Plan, which succeeds the 2015 plan that expired in 2025, and approved an amendment allowing a reverse stock split of 1-for-2 to 1-for-10 if the board chooses to effect one before June 30, 2027. Stockholders also elected Gregory D. Waller as a Class II director and approved share issuance on exercise of Series A-1 Preferred Investment Options. The filing does not say whether the board will use the reverse split authority.
Equity plan approved with 326,188 votes for, 149,113 against and 7,889 abstentions
Reverse split authority approved with 1,120,937 votes for and 138,084 against, usable until June 30, 2027
Gregory D. Waller elected Class II director with 377,954 votes for and 105,236 withheld, serving until 2029
Shares present at the meeting totaled 1,259,315, about 52.3% of shares outstanding on the record date
Orion Energy Systems said a longtime US retailer customer made a follow-on commitment for a new LED lighting project estimated at $10 million to $15 million, and raised its fiscal 2027 revenue outlook to $100 million to $102 million from $95 million to $97 million. The company said the timing of individual purchase orders is uncertain, and that Q2 revenue is expected to fall from the previously announced Q1 revenue of $25.7 million.
FY 2027 revenue outlook raised to $100 million to $102 million, up from $95 million to $97 million
New retailer project estimated at $10 million to $15 million; most revenue expected in the second half of fiscal 2027, which ends March 31, 2027
Fiscal Q2 revenue expected to decrease compared with Q1 revenue of $25.7 million
Company continues to expect positive Adjusted EBITDA for the fiscal year as a whole
LifeMD announced an exclusive collaboration with AT&T under which eligible AT&T wireless and fiber customers receive a complimentary LifeMD membership, with the $19 monthly fee waived. The filing does not quantify expected revenue or costs, but it states that LifeMD will initially pay AT&T a fixed fee per lead, and that the agreement runs for an initial one-year term with automatic renewals.
Eligible AT&T customers receive a LifeMD membership with a $228 annual value; the $19 monthly fee is fully waived.
The initial launch covers 29 million AT&T customers in 11 states, with additional markets joining in January 2027 as the program expands nationwide.
LifeMD will pay AT&T a fixed fee per lead, with later compensation to be negotiated; the agreement has a one-year initial term with automatic one-year renewals unless either party gives 90 days' written notice.
HealthStream issued 1,355,932 new shares to WJRJJ Ventures, LLC for about $40 million, and CEO Robert A. Frist, Jr. sold the investor 144,068 existing shares for about $4.25 million, both at $29.50 per share; the transaction closed September 14, 2026. The issuance increases the number of shares outstanding, and the company intends to use the net proceeds for general corporate purposes, including investment in its solutions, working capital and potential acquisitions. Because WJRJJ's owner has ties to Empath Nursing, a company in which HealthStream holds about 5%, the deal was approved by the audit committee and disinterested directors.
Company issued 1,355,932 new common shares at $29.50 each for about $40 million in cash, closing September 14, 2026.
CEO Robert A. Frist, Jr. sold 144,068 existing shares to WJRJJ Ventures for about $4.25 million at $29.50 per share.
Related-party link: WJRJJ owns about 42% of Empath Nursing, and HealthStream holds about 5% of Empath; the audit committee approved the deal and Mr. Frist abstained.
The investor is subject to standstill obligations for 12 months, and a registration rights agreement covers resale of the shares, with filing due within 45 days of an investor request.
Dream Finders Homes entered subscription agreements on September 14, 2026, selling 225,000 shares of Series B Convertible Preferred Stock for $225.0 million, and used the proceeds to redeem its Series A preferred stock. The company also agreed to sell 450,000 more Series B shares at a second closing, contingent on completing its previously announced merger with Beazer Homes USA, Inc., which would fund part of the merger consideration. The preferred stock ranks senior to common stock on dividends and liquidation, carries a 12.00% cumulative dividend, and can convert to Class A common stock at a discount after six years, so it adds a senior claim and potential dilution for common shareholders.
225,000 Series B shares sold at a first closing on September 14, 2026, for an aggregate $225.0 million, with a 2.50% original issue discount
Cumulative dividend of 12.00% per year, payable quarterly, with a maximum rate of 15.00% after step-ups
Additional 450,000 Series B shares to be sold at a second closing tied to the Beazer Homes USA merger conditions
Conversion not permitted by purchasers before the sixth anniversary of the First Closing, except in a Fundamental Change; conversion price floor of $4.19
WhiteHorse Finance said its board formed a special committee of independent directors to explore strategic alternatives, which could include a sale or other corporate transaction. The filing gives no timetable and says there is no assurance the review will lead to any transaction.
Board formed a special committee of independent directors on September 15, 2026
Review could include a sale or other corporate transaction
No timetable set; company will not comment further unless a course of action is approved, the review ends, or disclosure is required
Tredegar's board elected Cindy Yao as Vice President, Chief Financial Officer and Treasurer on September 14, 2026, effective September 21, 2026. The filing says the company is pursuing a transition from a holding-company structure toward an operating-company model, and the CEO said the new CFO will help with enterprise-level financial visibility and performance discipline.
Board elected Cindy Yao on September 14, 2026; start date is September 21, 2026
Annual base salary of $450,000, with a target bonus of 60% of base salary under the 2026 Short-Term Incentive Plan (maximum 120%)
Long-term incentive target of 80% of base salary, split 50% restricted stock and 50% non-equity cash
Prior roles include CFO of Holon Health from May 2026 and CFO of HF Foods Group from May 2024 through October 2025
5E Advanced Materials and its subsidiary 5E SVM agreed on September 14, 2026 to buy specified assets of Searles Valley Minerals and affiliates through a Section 363 sale in Chapter 11 bankruptcy, with consideration of about $3.4 million in cash, 8.3 million common shares, and a promissory note of about $6.2 million. The deal requires Bankruptcy Court approval, Surface Transportation Board authorization for railroad assets, and $10.0 million in bridge financing, and the company expects closing in early October 2026, which would add 8.3 million shares for shareholders and bring operating facilities, but the assets are being acquired as is and the sellers' representations will not survive closing.
5E SVM was selected as successful bidder on September 14, 2026 for assets including Argus, Westend and Trona facilities and about 9,000 acres of Searles Lake brine resources in San Bernardino County, California.
Consideration includes about $3.4 million in cash, 8.3 million shares of common stock, and a senior unsecured promissory note of about $6.2 million; a $300,000 deposit was made.
The company guarantees 5E SVM's cash payment obligation, and the Bridge Facility of $10.0 million carries 8.00% interest with a $1.0 million transaction fee.
The company expects closing in early October 2026; the outside date is October 2, 2026, extendable to October 16, 2026.
Cabot's board elected Vice President and Treasurer Steven J. Delahunt as Chief Financial Officer, effective October 1, 2026, on an interim basis. Erica McLaughlin, the current CFO, becomes President and Chief Executive Officer on the same date, succeeding Sean Keohane. The company is searching for a permanent CFO, and the filing contains no financial results.
Delahunt, who joined Cabot in 2010, serves as interim CFO effective October 1, 2026.
McLaughlin is elected President and CEO effective October 1, 2026, succeeding Sean Keohane.
Delahunt receives a monthly cash stipend of $35,000 while serving as interim CFO.
Delahunt was Vice President of Investor Relations from July 2016 through January 2026.
GT Biopharma entered into a securities purchase agreement on September 14, 2026, selling Series M 10% convertible preferred stock and warrants for an aggregate purchase price of $7,450,000, with up to $30,000,000 more available to purchasers through greenshoe rights. The preferred stock converts at an initial price of $6.10 per share and carries full ratchet price protection, so the potential dilution to existing shareholders could be substantial; the company also agreed to seek shareholder approval for issuances above 19.99% of outstanding common stock.
Aggregate purchase price of $7,450,000 for preferred stock and warrants with stated value of $8,277,778
Preferred stock and warrants have an initial price of $6.10 per share and full ratchet price protection
Purchasers may buy up to $33,333,333 of additional preferred stock for $30,000,000 under greenshoe rights
Company agreed to hold a stockholder meeting seeking approval for issuances above 19.99% of outstanding common stock
Santander Holdings USA, Inc. announced it will redeem all 135,000 outstanding shares of its Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock, Series I, and the 5,400,000 related depositary shares on October 15, 2026. Depositary Shares will be redeemed at $25.00 each, and the regular quarterly dividend will be paid separately to holders of record as of September 30, 2026. The filing is a routine capital action that removes this preferred issue and ends its dividend stream after the October payment.
Redemption date: October 15, 2026, for all 135,000 Series I preferred shares and 5,400,000 depositary shares
Redemption price: $25.00 per depositary share, excluding the regular quarterly dividend
Dividend declared earlier is payable October 15, 2026 to holders of record at close of business September 30, 2026
Depositary Shares trade on NYSE as SNUS PF I and are held through DTC; Broadridge Corporate Issuer Solutions is redemption agent
Scholar Rock disclosed that the FDA approved ISEMBYLD (apitegromab-mstn) for spinal muscular atrophy in adults and children 2 years and older receiving an SMN2-targeted treatment. The company also corrected management's statement during the September 14, 2026 investor call that the FDA required no post-marketing safety commitments, saying the FDA does require a pregnancy safety study and fracture alert reports.
FDA approved ISEMBYLD for SMA patients aged 2 and older currently on an SMN2-targeted treatment
FDA requires a post-marketing pregnancy safety study covering pregnancy complications and birth outcomes
FDA requested that all serious and non-serious fracture cases be submitted as 15-day alert reports
Correction was made to statements made in error during the September 14, 2026 investor call
Otis Worldwide said Chair, CEO and President Judith F. Marks will retire, effective on the earlier of her successor starting as CEO, expected in the first half of 2027, or July 31, 2027. A Board succession committee chaired by Christopher J. Kearney is searching internal and external candidates with Spencer Stuart, and the filing reports no financial results or guidance changes.
Judith F. Marks will resign from the Board on the Transition Date and from all other Company positions.
Transition Date is the earlier of her successor's start as CEO (expected first half of 2027) or July 31, 2027.
If the Transition Date falls before July 31, 2027, Marks serves as a non-employee senior advisor through that date with no cash compensation.
Her equity awards keep vesting during the advisory period, and she remains eligible for her 2026 annual bonus based on actual performance.
Intrusion and CEO Anthony Scott agreed on September 14, 2026 not to automatically renew his employment agreement, which ends November 15, 2026. Scott will keep his role, salary and benefits while the two sides negotiate a new agreement.
Agreement signed September 14, 2026; Scott's Executive Employment Agreement dated November 11, 2021 expires November 15, 2026
Scott remains President and Chief Executive Officer during the negotiation period
Existing base salary, benefits and duties continue under the current terms during negotiations
Vera Bradley reported second-quarter fiscal 2027 net revenues of $71.6 million, up 1.1% from a year earlier, and GAAP net income from continuing operations of $4.5 million, or $0.15 per diluted share, compared with a loss of $4.7 million a year earlier. The company reiterated its fiscal 2027 sales guidance of $255 million to $270 million and its expectation of at least a 50% improvement in its non-GAAP operating loss.
Net revenues rose 1.1% to $71.6 million from $70.9 million in the prior-year second quarter.
GAAP net income from continuing operations was $4.5 million, or $0.15 per diluted share, versus a loss of $4.7 million, or $0.17 per share, a year earlier.
Gross margin benefited from $7.7 million of tariff refunds; Indirect segment revenue fell 39.4% to $6.3 million.
Fiscal 2027 sales guidance of $255 million to $270 million and at least 50% operating loss improvement were reiterated.
LB Pharmaceuticals named Susan G. Kozauer, M.D. as its Chief Medical Officer, effective September 14, 2026, with a $515,000 base salary and an option to buy 200,000 shares. The company says she will lead clinical development of LB-102 ahead of Phase 3 NOVA-2 topline results expected in the first half of 2027.
Effective start date: September 14, 2026; base salary $515,000 with a 40% target bonus
One-time sign-on bonus of $150,000, with a 200,000-share option subject to four-year vesting
Severance: nine months of base salary and COBRA for up to nine months; enhanced terms apply within the change-of-control window
CEO Heather Turner said Phase 3 NOVA-2 topline results are expected in the first half of 2027
Cheetah Net Supply Chain Service Inc. signed an agreement to acquire all membership interests of JoyPak Supply LLC, a Nevada company that sells consumer, beauty, personal care and everyday-use products, for $788,000 in cash. The company said the deal would diversify its product mix into consumer categories, which currently center on logistics, warehousing and industrial equipment trading. The deal's size is small relative to the company's scope, and closing remains subject to due diligence and other conditions.
Purchase price is $788,000: an $88,000 initial payment within two business days and a $700,000 payment at closing.
Closing is expected on or about October 15, 2026, and must occur no later than four weeks after the agreement date.
If the deal terminates for reasons other than Cheetah's breach, the sellers must return the $88,000 initial payment.
The agreement was signed with Newland Asset Management LLC and Redwing Capital LLC.
Aspen Aerogels posted an investor presentation on its website dated September 15, 2026, furnished as Exhibit 99.1 to a Form 8-K under Regulation FD. The deck restates Q3 2026 guidance, dated August 6, 2026, that marks a return to positive Adjusted EBITDA, and sets a target of about $175 million revenue run-rate for Adjusted EBITDA breakeven by year-end 2027.
Q3 2026 guidance, as of August 6, 2026, marks a return to positive Adjusted EBITDA.
Last-twelve-months revenue through Q2 2026 was $202 million; cash and equivalents were $153.4 million as of June 30, 2026.
European thermal barrier revenue is outlined at $20 million to $30 million for 2026, with a target of $40 million to $60 million of European OEM revenue in 2027.
East Providence facility is in a staged restart after an April 2026 incident, with full restoration targeted for the first half of 2027.
Lindblad Expeditions acquired a 60% controlling interest in White Desert, PNR Airways and Echo Charlie for about $61 million in cash, plus about $6 million for balance-sheet cash, subject to customary true-up adjustments. The company also raised its full-year 2026 revenue, net yield and Adjusted EBITDA guidance to reflect the deal and continued strong performance across the business.
60% controlling interest in White Desert, PNR Airways and Echo Charlie for about $61 million cash, plus about $6 million for balance-sheet cash
Options to buy the remaining equity in two equal tranches, exercisable within 30 days of December 31, 2030 and 2031, priced on the companies' EBITDA at the time
Updated 2026 guidance: tour revenues of $850 - $880 million, net yield per available guest night of 5.5% - 6.5%, Adjusted EBITDA of $140 - $148 million
CEO Natalya Leahy called the transaction the largest in the company's history
BlossomHill Therapeutics presented updated Phase 1/2 SOLARA trial data for its investigational EGFR inhibitor BH-30643 in lung cancer patients with the EGFR C797S resistance mutation, at the IASLC 2026 World Conference on Lung Cancer. The filing reports a 45% objective response rate in 40 patients, which the company says has no approved targeted therapy, and it plans a Phase 2 study starting in Q1 2027.
Objective response rate of 45% (18 of 40 patients, 95% CI 29%-62%); disease control rate of 88% (35 of 40) as of the May 12, 2026 data cutoff
Treatment-related dose reductions and discontinuations occurred in 9% and 3% of 174 patients treated at 40 mg, 50 mg and 60 mg twice daily
Median follow-up was 6.9 months; the company plans a global Phase 2 study in EGFR C797S-positive NSCLC in Q1 2027
Presentation follows FDA Fast Track designation for BH-30643 in advanced or metastatic EGFR C797S-positive NSCLC
Axon announced a proposed offering of $1.0 billion of 0% convertible senior notes due 2031 and filed an amendment to its credit agreement that would raise its revolving credit facility from $300.0 million to $500.0 million, conditioned on the notes offering closing. The filing shows added borrowing capacity and potential share dilution, with proceeds partly used for capped call transactions and the rest for general corporate purposes, including possible acquisitions.
Proposed $1.0 billion of 0% convertible senior notes due September 15, 2031, with underwriters able to buy up to an additional $150.0 million.
Revolving facility expected to increase from $300.0 million to $500.0 million, with an option to add $150.0 million more; maturity extended to up to five years from closing.
Part of net proceeds will pay for capped call transactions meant to reduce potential dilution; the remainder is for general corporate purposes, which may include acquisitions.
Noteholders may require repurchase on March 20, 2031, and Axon may settle conversions in cash, shares, or both.
Driven Brands announced updated capital allocation priorities on September 15, 2026, including a $100 million share repurchase authorization effective that day and a long-term net leverage target of 2-3x Net Debt to Adjusted EBITDA. The company said it reduced net leverage from 5.0x at the end of 2023 to an expected 3.0x at the end of Q3 2026, and the buyback equals about 5% of its market capitalization, so the plan directly affects shareholder returns.
$100 million share repurchase authorization, effective September 15, 2026, with no stated expiration date
Company is not obligated to repurchase shares and may discontinue the program at any time; purchases will be funded from cash balances and cash flows
Net leverage target set at 2-3x Net Debt to Adjusted EBITDA; company expects 3.0x at end of Q3 2026, a quarter ahead of plan
Company will continue investing in Take 5 growth, which may include acquisitions where attractive
Rocket Pharmaceuticals said the U.S. Food and Drug Administration confirmed continued enrollment and dosing under a modified protocol for its global pivotal Phase 2 trial of RP-A501 in Danon disease, along with a 12-patient pivotal population and established 12-month co-primary endpoints. The alignment is a regulatory milestone for the program, and the company said it expects to complete dosing of the remaining patients by mid-2027.
FDA confirmed a pivotal population of 12 male patients treated at the recalibrated dose of 3.8 × 10¹³ GC/kg.
The first three patients treated under the modified protocol count toward the 12-patient pivotal population, leaving nine to be enrolled and treated.
Primary assessment at 12 months uses myocardial LAMP2 protein expression and a 10% reduction from baseline in left ventricular mass index as co-primary endpoints.
Rocket plans a Danon disease program webinar on October 6, 2026, at 4:30 p.m. ET.
Connect Biopharma reported topline results from its 160-patient Phase 2 Seabreeze STAT Asthma study of rademikibart as an add-on to standard of care for acute asthma exacerbations. The primary endpoint, treatment failure over 28 days, did not reach statistical significance (p=0.153), although the company reported a 66% reduction versus placebo, while the key secondary endpoint, post-bronchodilator FEV1 at Day 7, was statistically significant (p=0.023). The company plans to report COPD study data later this month and then meet with the FDA on a Phase 3 program.
Treatment failure rate over 28 days was 2.5% (2 of 79) with rademikibart versus 7.4% (6 of 81) with placebo; p=0.153, not statistically significant
Post-bronchodilator FEV1 on Day 7 rose 250 mL with rademikibart versus 120 mL with placebo, a 130 mL difference (p=0.023)
One serious adverse event was reported in the rademikibart arm versus three in the placebo arm; no AEs led to study discontinuation in either arm
Seabreeze STAT COPD study topline data expected later in September 2026; company plans to engage the FDA on a Phase 3 program afterward
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.